Drug Trial Radar · NCT03149640
Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
850
Actual
Start
Jul 19, 2017
Primary completion
Mar 9, 2021
Study completion Jun 17, 2021
Sponsor
- Lead sponsor
- University Hospital, ToursAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to prove that after the third day of invasive mechanical ventilation a three-day course of inhaled amikacin reduces the incidence of subsequent VAP. Parallel two group double blind randomized controlled clinical trial. Individual randomization, performed on day 4 of invasive mechanical ventilation, will be stratified on centre in order to account for variations in VAP prevention bundle implementation and use of systemic antibiotics the day of randomization. Patients will be treated three consecutive days with inhaled amikacin or placebo. Patients will be followed up daily in the intensive care unit for the occurrence of VAP according to international guidelines until day 28.
Conditions
- Pneumonia, Ventilator-Associated
Interventions
Inhaled amikacinDrug
Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
Inhaled placeboDrug
Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of a first VAP episode from randomization to day 28Time frame: Patients will be followed from randomization to day 28
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Service de Réanimation Chirurgicale
Angers, France
Service de Réanimation Médicale - CH d'Angoulême
Angoulême, France
Service de Réanimation Polyvalente
Argenteuil, France
Service de Réanimation Médicale - Hôpital Louis Mourier
Colombes, France
Service de Réanimation
Dijon, France
Service de Réanimation Médicale - CHD Les Oudairies
La Roche-sur-Yon, France
Service de Réanimation
Le Mans, France
Service de Réanimation Médicale - Hôpital La Croix-Rousse
Lyon, France
Service de Réanimation Médicale
Orléans, France
Service de Réanimation Médicale - Hôpital Pitié Salpêtrière
Paris, France
Service de Réanimation Médicale - CHU La Milétrie
Poitiers, France
Service de Réanimation Médicale
Poitiers, France
Service de Réanimation Médicale - CHU Pontchaillou
Rennes, France
Service de Réanimation Médicale - CHU Rouen
Rouen, France
Service de Réanimation Médicale - Hôpital Charles Nicolle
Rouen, France
Service de Réanimation - NHC
Strasbourg, France
Service de Réanimation Médicale - Hôpital de Hautepierre
Strasbourg, France
Service de Réanimation médicale, Hôpital Trousseau
Tours, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.